The Patent Trial and Appeal Board ruled against the generic drugmaker's inter partes review seeking to overturn the patent covering Tecfidera. The drug, which had $4.4 billion in sales last year, could remain protected through February 2028.
An analyst wrote that while the new drug, Vumerity, has a good chance of winning FDA approval later this year, it is uncertain whether the superior gastrointestinal tolerability it demonstrated will be enough to protect Tecfidera from generic competition.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.